Jaguar Health, Inc. Stock News

Shares of JAGX stock are flying higher after the FDA granted conditional approval for its chemotherapy-induced diarrhea treatment. The post JAGX Stock Alert: 5 Things to Know About the News Sending Ja

Which penny stocks are you watching right now? The post Trending Penny Stocks to Buy Today?

During the last session, Jaguar Health Inc. (NASDAQ:JAGX)s traded shares were 1.51 million, with the beta value of the company hitting 1.64. At the end of the trading day, the stocks price was $1.15, reflecting an intraday loss of -0.86% or -$0.01. The 52-week high for the JAGX share is $13.41, that puts it down Jaguar Health Inc. (NASDAQ: JAGX) Rose 16.52% From Its 52-Week Low; YTD Numbers Fall -52.97% Here Are Some Things To Keep In Mind Read More »

The recognition of Orphan Drug Designation in Europe for crofelemer for this rare disease is the first key milestone of Napo EU under the company''s exclusive license agreement with Jaguar HealthSAN

(PR-inside.com) The recognition of Orphan Drug Designation in Europe for crofelemer for this rare disease is the first key milestone of Napo EU under the company''s exclusive license agreement with Jaguar Health SAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / December 13, 2021 / Jaguar Health (NASDAQ:JAGX) and its majority owned Italian subsidiary, Napo EU S.p.A. (soon to be renamed Napo Therapeutics), today announced that the European Commission has adopted the decision to grant Orphan Drug Designation (ODD) for crofelemer for the indication of short bowel syndrome (SBS) in the European Union following review of the ODD application Napo EU submitted ..

(PR-inside.com) Results of the study provide the first proof-of-concept data for potential use of crofelemer - a novel, oral, plant-based, non-opioid antidiarrheal prescription medication - in breast cancer patients SAN FRANCISCO, CA / ACCESSWIRE / December 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) and its wholly owned subsidiary Napo Pharmaceuticals today announced the third-party presentation of findings from the investigator-initiated HALT-D trial evaluating crofelemer for preventing chemotherapy-induced diarrhea (CID) in HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab and a taxane. These therapies cause CID in up to 80% of breast cancer patients, reaching grade 3, which often requires hospitalization, in ..

With 2021 coming to an end, which penny stocks are you watching? The post Top Penny Stocks to Add to Your Watchlist As 2021 Ends appeared first on Penny Stocks to Buy, Picks, News and Information | Pe

With 2021 coming to an end, which penny stocks are you watching? The post Top Penny Stocks to Add to Your Watchlist As 2021 Ends appeared first on Penny Stocks to Buy, Picks, News and Information | Pe

The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased by over 8% this week. This is why it happened.

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S

During the last session, Jaguar Health Inc. (NASDAQ:JAGX)s traded shares were 0.8 million, with the beta value of the company hitting 1.57. At the end of the trading day, the stocks price was $1.38, reflecting an intraday loss of -3.50% or -$0.05. The 52-week high for the JAGX share is $13.41, that puts it down During The Past Six Months, Jaguar Health Inc. (NASDAQ: JAGX) Shares Took An -71.25% Jump. Here Is What We Should Expect Read More »

In the last trading session, 1.4 million shares of the Jaguar Health Inc. (NASDAQ:JAGX) were traded, and its beta was 1.57. Most recently the companys share price was $1.38, and it changed around -$0.13 or -8.61% from the last close, which brings the market valuation of the company to $61.60M. JAGX currently trades at a Jaguar Health Inc. (NASDAQ: JAGX): A Business Review And Growth Forecast Read More »

Jaguar Health (NASDAQ:JAGX) issued its earnings results on Wednesday. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.09), MarketWatch Earnings reports. Jaguar Health had a negative net margin of 612.54% and a negative return on equity of 205.92%. During the same quarter last year, []